Lambda free light chains (LFLC) measures in cerebrospinal fluid (CSF) may reflect early CNS inflammation, but their prognostic value in early relapsing–remitting multiple sclerosis (RRMS) remains unclear. This study evaluated whether baseline LFLC-related parameters are associated with risk of second relapse, MRI activity and progression to Expanded Disability Status Scale (EDSS) ≥ 4.
This single-centre retrospective study enrolled patients aged ≥ 18 years with RRMS who had experienced no more than one clinical relapse at lumbar puncture and had baseline paired CSF/serum FLC measurements. Baseline LFLC parameters, including CSF LFLC concentration, LFLC index, CSF LFLC/IgG ratio, CSF KFLC/LFLC ratio and oligoclonal LFLC bands, were analysed in relation to clinical and radiological outcomes using Cox proportional hazards models.
The analyses included 91 RRMS patients: 65.9% female; median age at disease onset, 34.7 years (IQR 15.4) and median follow-up period, 36 months (IQR 25). Baseline LFLC-related measures were not associated with the risk of second relapse, MRI activity or progression to EDSS ≥ 4 in multivariable analyses. The number of CSF-restricted oligoclonal LFLC bands was associated with reaching EDSS ≥ 4 in univariable analysis (HR 1.09, 95% CI 1.01–1.17); however, this association was not confirmed after adjustment for baseline EDSS and treatment exposure.
LFLC-related measures were not independently associated with relapse risk, MRI activity or disability progression to EDSS ≥ 4 in early RRMS. These findings suggest limited prognostic value of LFLC biomarkers in early disease stages and support the need for further prospective multicentre studies.



